Retina

Current options, challenges in developing novel therapies.

According to investigators, the virtual reality option could overcome hurdles associated with reliance on a physical course.

Assessment of renal function could help explain the treatment response for patients with diabetic macular oedema.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.

Teleretinal screening programs prove a cost-effective option in preventing blindness related to diabetic retinopathy.

Imaging study revealed specific retinal and choroidal changes associated with Parkinson's disease.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Chirag Jhaveri, MD, reviews the trial design and results of the LADDER and ARCHWAY studies, which tested the port delivery system in neovascular AMD.

Underlying autoimmune disease alters uveitis therapy.

Surgical options facilitate increased durability for patients with retinal degeneration.

Expert insight on the history of the port delivery system in neovascular AMD and how it has impacted patient experience and outcomes.

Confronting issues unique to aging may lead to better outcomes.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Mark Wieland noted that the port delivery system with ranibizumab provides drug delivery over an extended period.

Dr Sunir J. Garg speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Ines Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Dr Ajay Kuriyan discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular oedema in clinical trial setting."

Dr Roger A. Goldberg, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.

During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Dilsher Dhoot reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular oedema.

Intra-arterial tPA treatment could provide benefits for patients with central retinal artery occlusion.

A recently developed tool can help ophthalmologists to assess the quality of findings from real-world studies in retinal diseases. This will help them decide which results are most robust and applicable to their practice.

Dr Timothy G. Murray discusses the 5-year followup data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.

Dr Nathan Steinle discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.